medigraphic.com

2007, Número S1

<< Anterior Siguiente >>

Arch Cardiol Mex 2007; 77 (S1)


3. Choque cardiogénico por síndrome isquémico coronario agudo sin complicaciones mecánicas

Lupi HE, González PH

Idioma: Español
Referencias bibliográficas: 36
Paginas: 34-38
Archivo PDF: 67.12 Kb.


FRAGMENTO

Introducción

El choque cardiogénico (CC) es la causa más común de muerte en cardiópatas con infarto agudo del miocardio (IAM) que llegan al hospital, y su incidencia ha permanecido constante en las últimas 3 décadas. En el período de 1975 a 1977, los enfermos hospitalizados por IAM sin CC, presentaban una mortalidad del 12%, comparado con el 72% de los enfermos que desarrollan CC.
Típicamente, se ha considerado que el CC resulta de un daño masivo al miocardio del ventrículo izquierdo (vi). En el registro del estudio SHOCK la causa principal de CC fue insuficiencia ventricular izquierda en el 78.5%, las complicaciones mecánicas en el 12% y la disfunción del ventrículo derecho en el 2.8%. La confirmación de la etiología específica del CC tiene una gran importancia en la terapéutica adecuada.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. HOCHMAN JS: Cardiogenic Shock Complicating Acute Myocardial Infarction. Expanding the Paradigm. Circulation 2003; 107: 2998-3002.

  2. HOCHMAN JS, SLEEPER LA, WEBB JG, ET AL: Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999; 341: 625-634.

  3. GOLDBERG RJ, SAMAD NA, YARZEBSKI J, ET AL: Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999; 340: 1162-1168.

  4. LINDHOLM MG, KOBER L, BOESGAARD S, ET AL, on behalf of the TRACE study group: Cardiogenic shock complicating acute myocardial infarction. Prognostic impact of early and late shock development. Eur Heart J 2003; 24: 258-265.

  5. KILLIP T: Cardiogenic shock complicating myocardial infarction. J Am Coll Cardiol 1989; 14: 47-48.

  6. HOCHMAN JS, BULLER CE, SLEEPER LA, ET AL, for the SHOCK investigators: Cardiogenic shock complicating acute myocardial infarction. Etiologies, management and outcome: A report from the SHOCK trial registry. J Am Coll Cardiol 2000; 36: 1063-1070.

  7. ALONSO DR, SCHEIDT S, POST M, ET AL: Pathophysiology of cardiogenic shock: quantification of myocardial necrosis, clinical, pathologic and electrocardiographic correlations. Circulation 1973; 48: 588-596.

  8. HOLMES DR, BATES ER, KLEIMAN NS, ET AL: Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience. J Am Coll Cardiol 1995; 26: 668-674.

  9. HASDAI D, HARRINGTON RA, HOCHMAN JS, ET AL: Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J Am Coll Cardiol 2000; 36: 685-692.

  10. HASDAI D, HOLMES DR, TOPOL EJ, ET AL: Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase: Results from GUSTO III. Eur Heart J 1999; 20: 128-135.

  11. HOLMES DR, BEGER PB, HOCHMAN JS, ET AL: Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation 1999; 100: 2067-2073.

  12. HASDAI D, CALIFF RM, THOMPSON TD, ET AL: Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 2000; 35: 136-143.

  13. HOLZER J, KARLINER JS, O´ROURKE RA, PITT W, ROSS J: Effectiveness of dopamine in patients with cardiogenic shock. Am J Cardiol 1973; 32: 79-84.

  14. GOLDBERG LI, HSIEH YY, RESNEKOV L: Newer catecholamines for treatment of heart failure and shock: an update on dopamine and first look at dobutamine. Prog Cardiovasc Dis 1977; 19: 327-340.

  15. MOYER J, SKELTON J, MILLIS L: Norepinephrine: effect in normal subjects; use in treatment of shock unresponsive to other measures. Am J Med 1953; 15: 330-343.

  16. TUTTLE RR, MILLIS J: Dobutamine: development of a new catecholamine to selective increase cardiac contractility. Circ Res 1975; 36: 185-196.

  17. GILLESPIE TA, AMBOS HD, SOBEL BE, ROBERTS R: Effects of dobutamine in patients with acute myocardial infarction. Am J Cardiol 1977; 39: 588-594.

  18. KEUNG EC, SISKIND SJ, SONNEBLICK EH, RIBNER HS, SCHWARTZ WJ, LEJEMTEL TH: Dobutamine therapy in acute myocardial infarction. JAMA 1981; 245: 144-146.

  19. BENOTTI JR, GROSSMAN W, BRAUNWALD E, DAVALOS DD, ALOUSI AA: Hemodynamic assessment of amrinone. A new inotropic agent. N Engl J Med 1978; 299: 1373-1377.

  20. MILLARD RW, DUBE G, GRUPP G, GRUPP I, ALOUSI A, SCHWARTZ A: Direct vasodilator and positive inotropic actions of amrinone. J Moll Cell Cardiol 1980; 12: 647-652.

  21. JASKI BE, FIFER MA, WRIGHT RF, BRAUNWALD E, COLUCCI WS: Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest 1985; 75: 643-649.

  22. GAGE J, RUTMAN H, LUCIDO D, LEJEMTEL TH: Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 1986; 74: 367-373.

  23. BRISTOW MR, GINSBURG R, MINOBE W, CIBICCIOTTI RS, SAGEMAN WS, ET AL: Decreased catecholamine sensitivity an beta –adrenergic –receptor density in failing human hearts. N Engl J Med 1982; 307: 205-211.

  24. COHN JN , BURKE LP: Nitroprusside. Ann Intern Med 1979; 91: 752-757.

  25. FLAHERTY JT, BECKER LC, BULKLEY BH, WEISS JL, ET AL: A randomized trial of intravenous nitroglycerin in patients with acute myocardial infarction. Circulation 1983; 68: 576-588.

  26. CHATTERJEE K: Vasodilator therapy for heart failure. Ann Intern Med 1975; 83: 421-423.

  27. GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.

  28. Gruppo Italiano per lo Studio Della Streptochinasi Nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 2: 397-402.

  29. ISIS-2 Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.

  30. SANBORN TA, SLEEPER LA, BATES ER, ET AL: Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries for cardiogenic shock? J Am Coll Cardiol 2000; 36(3 Suppl A): 1123-1129.

  31. HOCHMAN JS, SLEEPER LA, WHITE HD, ET AL: One-year survival following early revascularization for cardiogenic shock. JAMA 2001; 285: 190-192.

  32. HOCHMAN JS, SLEEPER LA, WEBB JG, ET AL: Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999; 341: 625-634.

  33. HOCHMAN JS: Cardiogenic Shock Complicating Acute Myocardial Infarction. Expanding the Paradigm. Circulation 2003; 107: 2998-3002.

  34. COTTER G, BLATT A, KALUSKI E, ET AL: LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 2003; 24; 1287-1295.

  35. ARGENZIANO M, CHEN JM, CHOUDHRI AF, ET AL: Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. Thorac Cardiovasc Surg 1998; 116: 973-980.

  36. HOLMES CL, PATEL B, RUSSELL JA, WALLEY KR: Physiology of vasopressin relevant to management of septic shock. Chest 2001; 120: 989-1002.




2020     |     www.medigraphic.com